POLBF News and Press, Poolbeg Pharma plc Ord GBP 0.0002 From 03/30/23

(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after publishing final results for 2022 that show that the clinical-stage biotech company finished its first full year of operations with £16.2mln. Skillington describes it as a "very h...

Results for the year ended 31 December 2022 Significant milestones reached, well capitalised and positioned for future growth LONDON, UK / ACCESSWIRE / March 30, 2023 / Poolbeg Pharma Plc (AIM:POLB)(OTCQB:POLBF) ("Poolbeg" or the "Company") a leading biopharmaceutical company focusing o...

(NewsDirect) Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new report on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), following the release of selected data from its human volunteer LPS challenge trial for lead molecule POLB 001. Contact Details ...

(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing the data readout from an LPS human challenge trial for POLB 001, the infectious disease focused biopharma company's lead molecule. Skillington says that ...

(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) VP of Business Development David English speaks to Proactive's Thomas Warner about the work he's doing to progress the clinical stage infectious disease pharmaceutical company's lead asset POLB 001. English says that Poolbeg is "...

(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing that the company has submitted a patent application for the use of POLB 001 in a new oncological indication. Skillington explains the reasons for the strategic e...

Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications Key Highlights · Newly filed patent application to protect use of POLB 001 for new oncology indicationScientific findings indicate POLB ...

(NewsDirect) Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates t...

Early data read out indicates a successful LPS human challenge trial Key Highlights POLB 001 demonstrated a marked reduction in both systemic and localised inflammatory response compared to volunteers who received placebo A clear dose-response relationship was demonstrated We...

Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme Collaboration with OneThree Biotech identifies novel RSV treatments First time RSV drug candidates identified using AI Candidates with existing Pha...